GSK Premium Antiallergy Xyzal (Levocetirizine Dihydrochloride) 5mg Tablets – 100 Tablets

Recommended Household Medicine from Japan | Xyzal (Levocetirizine) 5mg — A Potent Antihistamine for Chronic Urticaria and Allergies

With environmental changes and faster-paced lifestyles, the incidence of allergic diseases is continuously rising, affecting many people who suffer from conditions like rhinitis and urticaria. Japan, as a leading country in allergy drug development, offers the highly effective and low side-effect medication “Levocetirizine” (brand name: Xyzal) produced by Mitsubishi Tanabe Pharma. It has become a top choice for many families and healthcare professionals. This article will provide a detailed introduction to the drug’s ingredients, efficacy, dosage, and precautions to help users take medicine scientifically and live healthily.

1. Product Overview

Levocetirizine is the active enantiomer of cetirizine, a long-acting and highly selective histamine H1 receptor antagonist. It works by blocking histamine from binding to H1 receptors in the body, thereby suppressing various allergic symptoms such as:

Skin itching and urticaria

Nasal congestion, sneezing, and runny nose (as seen in allergic rhinitis)

Eye itching and tearing (symptoms of allergic conjunctivitis)

2. Specifications

Package: 100 tablets (10 tablets per blister pack × 10 packs)

3. Appearance

White film-coated tablets with double-sided score marks

4. Ingredients

Active Ingredient:

Each tablet contains 5 mg of Levocetirizine Hydrochloride as the main active component. Levocetirizine selectively blocks histamine H1 receptors to relieve symptoms such as nasal congestion, runny nose, sneezing, skin itching, and urticaria caused by allergies.

Excipients (Additives):

To ensure stability, compressibility, taste, and disintegration of the tablets, the following excipients are included:

Microcrystalline Cellulose: filler and binder to improve tablet strength

Light Anhydrous Silicic Acid: anti-caking and flow aid

Lactose Hydrate: diluent for proper tablet size and ease of swallowing

Magnesium Stearate: lubricant to prevent powder sticking during compression

Hypromellose (HPMC): film coating agent to control drug release and enhance stability

Titanium Dioxide: white pigment and light blocker to protect the drug

Polyethylene Glycol 400: plasticizer to improve coating flexibility and texture

5. Indications

Adults:

Allergic rhinitis

Urticaria, eczema, dermatitis, prurigo, and other itching skin conditions

Children:

Allergic rhinitis

Urticaria and itching associated with skin diseases such as eczema, dermatitis, and prurigo

6. Dosage and Administration

Adults:

Typically, 5 mg of Levocetirizine Hydrochloride once daily orally before bedtime. Dosage can be adjusted based on age and symptoms but should not exceed 10 mg per day.

Children (7 to under 15 years old):

Typically, 2.5 mg twice daily orally, after breakfast and before bedtime.

7. Precautions

General:

This medication may cause drowsiness; patients should avoid driving or operating machinery during treatment.

If no improvement is observed, avoid prolonged, aimless use and consult a healthcare provider for treatment adjustment.

For Allergic Rhinitis:

For seasonal allergic rhinitis, it is advisable to start treatment just before the high-risk season and continue until the season ends for better control and prevention.

8. Adverse Reactions

Serious but Rare:

Shock and anaphylactic reactions (frequency unknown): symptoms may include breathing difficulty, low blood pressure, urticaria, and redness.

Convulsions (frequency unknown)

Liver dysfunction (approximate incidence 0.6%) and jaundice (frequency unknown): may present with elevated AST, ALT, γ-GTP, LDH, ALP, accompanied by fatigue, loss of appetite, fever, nausea, and possible jaundice.

Thrombocytopenia (frequency unknown): watch for unexplained bleeding or bruising.

9. Contraindications

Patients with a known hypersensitivity to any components of this drug or to piperazine derivatives (such as cetirizine or hydroxyzine).

Patients with severe renal impairment (creatinine clearance less than 10 mL/min).